NCT05914688View on ClinicalTrials.gov

A Study to Compare Two Formulations of LY3209590 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

June 26, 2023

Primary Completion Date

January 18, 2024

Study Completion Date

January 18, 2024

Conditions
Healthy
Interventions
DRUG

LY3209590 (Formulation 1)

Administered SC.

DRUG

LY3209590 (Formulation 2)

Administered SC.

Trial Locations (1)

138623

Lilly Centre for Clinical Pharmacology, Singapore

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT05914688 - A Study to Compare Two Formulations of LY3209590 in Healthy Participants | Biotech Hunter | Biotech Hunter